Osteoporosis treatment options - down to the bare bones

It is World Osteoporosis Day this month, and Ben Hargreaves takes a look at what treatment options look like for patients living with the disease.

NICE ends UK access disparity to osteoporosis drug Evenity

NICE has reversed its stance on UCB and Amgen's severe osteoporosis therapy Evenity, saying out can be prescribed on the NHS for women with the disease in England and Wales who are at high

Cancer update buoys Amgen despite Q2 sales fall

CHMP says no to Amgen’s osteoporosis drug Evenity

At long last, Amgen/UCB score FDA okay for Evenity

Amgen and UCB finally have FDA approval for osteoporosis drug Evenity, two years after it was turned down by the regulator because of safety concerns.

Amgen and UCB re-file Evenity for US approval

Amgen and UCB have resubmitted their application for US approval of Evenity as an osteoporosis treatment, hoping that the additional data they have provided will help overcome the FDA’s pre